176391-41-6

176391-41-6 structure

Name: ONO 1301
Chemical Name: ono-1301
CAS Number: 176391-41-6
Molecular Formula: C₂₆H₂₄N₂O₄
Molecular Weight: 428.48000
Catalog: Signaling Pathways GPCR/G Protein Prostaglandin Receptor
Create Date: 2016-08-07 19:55:22
Modify Date: 2024-01-02 11:34:18
ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig[1][2][3].

Name	ono-1301
Synonyms	2-((5-(2-(((phenyl(pyridin-3-yl)methylene)amino)oxy)ethyl)-7,8-dihydronaphthalen-1-yl)oxy)acetic acid Acetic acid, ((7,8-dihydro-6-methyl-5-(2-(((phenyl-3-pyridinylmethylene)amino)oxy)ethyl)-1-naphthalenyl)oxy)- 7,8-Dihydro-5-[(E/Z)-[[α-(3-pyridyl)benzylidene]aminooxy]ethyl]-1-naphthyloxy]acetic acid

Description	ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig[1][2][3].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> GPCR/G Protein >> Prostaglandin Receptor
In Vitro	ONO 1301 (ONO-AP 500-02) inhibits collagen-induced aggregation in a concentration-dependent manner, with an IC50 value of 460 nM[3]. ONO-1301 (0-1000 nM) significantly increases alkaline phosphatase (ALP) activity in the primary osteoblasts and ST2 cells[3].
In Vivo	ONO-1301 (6 mg/kg; p.o.; /daily for 4 weeks) improves the hemodynamic status of rats with dilated cardiomyopathy after experimental autoimmune myocarditis[1]. Animal Model: Eight-week-old male Lewis rats (rat model of myosin-induced experimental autoimmune myocarditis)[1] Dosage: 6 mg/kg Administration: Orally; /daily for 4 weeks Result: Hemodynamic parameters and plasma brain natriuretic peptide (BNP) level were significantly improved.
References	[1]. Hirata Y, et al. Beneficial effect of a synthetic prostacyclin agonist, ONO-1301, in rat autoimmune myocarditis model. Eur J Pharmacol. 2013;699(1-3):81-87. [2]. Kashiwagi H, et al. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice. J Pharmacol Exp Ther. 2015;353(2):269-278. [3]. Kanayama S, et al. ONO-1301 Enhances in vitro Osteoblast Differentiation and in vivo Bone Formation Induced by Bone Morphogenetic Protein. Spine (Phila Pa 1976). 2018;43(11):E616-E624.

Melting Point	147-158 °C
Molecular Formula	C₂₆H₂₄N₂O₄
Molecular Weight	428.48000
Exact Mass	428.17400
PSA	81.01000
LogP	4.73390
Storage condition	-20° C

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
RIDADR	NONH for all modes of transport

176391-41-6	1351635-67-0
2250210-69-4	1802079-40-8
459841-96-4	1351636-18-4
1622212-25-2	250605-97-1
180197-87-9	185517-21-9
2301067-56-9	2301068-37-9
2301068-38-0	2301068-02-8
2301068-87-9	2301067-98-9
2301071-84-9	2301069-06-5
2301067-58-1	2301067-14-9